Drug Profile

Brelovitug - Bluejay Therapeutics

Alternative Names: BJT-778

Latest Information Update: 11 Dec 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Novartis
Developer Bluejay Therapeutics
Class Antivirals; Monoclonal antibodies
Mechanism of Action Hepatitis B surface antigen inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Hepatitis D
New Molecular Entity Yes

Highest Development Phases

Phase III Hepatitis D
Phase II Hepatitis B

Most Recent Events

08 Dec 2025 Bluejay Therapeutics plans potential BLA submission and launch in 2027
10 Nov 2025 Efficacy and adverse events data from phase II/III AZURE 1 clinical trials in Hepatitis D released by Bluejay Therapeutics
10 Nov 2025 Pharmacodynamics data from preclinical trial in Hepatitis D released by Bluejay Therapeutics

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com